Scarica l'app Stockscreener
36.59
1.61%
0.58
Dopo l'orario di chiusura:
36.90
0.31
+0.85%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$36.01
Aprire:
$36.11
Volume 24 ore:
1.97M
Relative Volume:
0.51
Capitalizzazione di mercato:
$15.42B
Reddito:
$2.26B
Utile/perdita netta:
$1.09B
Rapporto P/E:
15.62
EPS:
2.3431
Flusso di cassa netto:
$2.70B
1 W Prestazione:
+3.16%
1M Prestazione:
+1.25%
6M Prestazione:
+17.80%
1 anno Prestazione:
+27.62%
Intervallo 1D:
$36.00
$36.66
Intervallo di 1 settimana:
$35.31
$36.66
Portata 52W:
$24.05
$36.89
Royalty Pharma Plc Stock (RPRX) Company Profile
Nome
Royalty Pharma Plc
Settore
Industria
Telefono
(212) 883-0200
Indirizzo
110 EAST 59TH STREET, NEW YORK, NY
Confronta RPRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
36.59 | 15.17B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-16 | Iniziato | Morgan Stanley | Overweight |
| 2024-06-03 | Downgrade | UBS | Buy → Neutral |
| 2022-06-14 | Ripresa | UBS | Buy |
| 2022-05-13 | Iniziato | Scotiabank | Sector Outperform |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-14 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-30 | Iniziato | Tigress Financial | Buy |
| 2020-11-09 | Aggiornamento | UBS | Neutral → Buy |
| 2020-07-14 | Iniziato | Evercore ISI | In-line |
| 2020-07-13 | Iniziato | BofA Securities | Buy |
| 2020-07-13 | Iniziato | Citigroup | Neutral |
| 2020-07-13 | Iniziato | Cowen | Outperform |
| 2020-07-13 | Iniziato | Goldman | Neutral |
| 2020-07-13 | Iniziato | JP Morgan | Neutral |
| 2020-07-13 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Iniziato | SunTrust | Buy |
| 2020-07-13 | Iniziato | UBS | Neutral |
Mostra tutto
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by New York State Common Retirement Fund - MarketBeat
Winners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance
21,158 Shares in Royalty Pharma PLC (NASDAQ:RPRX) Acquired by Edgestream Partners L.P. - MarketBeat
What analysts say about Royalty Pharma plc stockTremendous portfolio expansion - jammulinksnews.com
Vestor Capital LLC Buys New Shares in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Is Royalty Pharma plc a good long term investmentTriple-digit returns - jammulinksnews.com
What drives Royalty Pharma plc stock pricePhenomenal wealth increase - Autocar Professional
Royalty Pharma plc Stock Analysis and ForecastOverwhelming profit margins - jammulinksnews.com
Citigroup Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Citigroup maintains Buy rating, raises PT for Royalty Pharma to $42. - AInvest
Citi raises Royalty Pharma stock price target to $42 on CF and Tremfya growth - Investing.com Nigeria
Royalty Pharma (RPRX) PT Raised to $42 at Citi - StreetInsider
Royalty Pharma PLC to Issue Quarterly Dividend of $0.22 (NASDAQ:RPRX) - MarketBeat
C WorldWide Group Holding A S Acquires New Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Los Angeles Capital Management LLC Grows Holdings in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Stake Raised by Victory Capital Management Inc. - MarketBeat
Morgan Stanley Raises Royalty Pharma (RPRX) Price Target, Maintains Overweight Rating - MSN
Cullen Frost Bankers Inc. Acquires 247,903 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Reaches New 52-Week HighTime to Buy? - MarketBeat
Royalty Pharma Declares Q3 2025 Dividend of $0.22 per Class A Share - AInvest
Royalty Pharma Declares Q3 2025 Dividend of $0.22 per Class A Ordinary Share - AInvest
Royalty Pharma Declares Third Quarter 2025 Dividend - The Globe and Mail
Royalty Pharma announces $0.22 per share dividend for Q3 2025 - Investing.com
Royalty Pharma plc (RPRX) Declares $0.22 Quarterly Dividend; 2.5% Yield - StreetInsider
Royalty Pharma Announces Q3 2025 Dividend of $0.22 per Share - AInvest
How to Take Advantage of moves in (RPRX) - news.stocktradersdaily.com
Bryn Mawr Capital Management LLC Boosts Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Is Royalty Pharma plc stock a good hedge against inflationHigh Potential Safe Trades - Newser
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman To Board - citybiz
Royalty Pharma adds two independent directors to board By Investing.com - Investing.com India
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors - The Manila Times
Royalty Pharma adds two independent directors to board - Investing.com
Royalty Pharma Appoints Two New Independent Directors, Boosting Independent Board Representation to Over 90% - Quiver Quantitative
Royalty Pharma Appoints Denali CMO and Warburg Pincus Veteran to Board Following Major Acquisition - Stock Titan
Royalty Pharma Plc Azioni (RPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):